Back to Newsroom

Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Third Fiscal Quarter and Nine Months Ended December 31, 2016

BASEL, Switzerland, Feb. 14, 2017 /PRNewswire/ — Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced corporate updates and reported financial results for the third fiscal quarter ended December 31, 2016.

“We look forward to a transformational year ahead for Axovant,” stated Vivek Ramaswamy, Chief Executive Officer of Axovant Sciences. “Our clinical programs are on-track to produce results from multiple late-stage clinical studies in 2017, and we continue to prepare for the potential commercial launches of those drugs if we receive marketing approval. In addition, we recently completed a financing that provides additional flexibility to advance or expand our pipeline.”

Click here to read the full release